Abstract: A multimedia streaming device can include a first circuit board configured to provide user controls and a second circuit board electrically coupled with the first circuit board and configured to provide content processing. The multimedia streaming device can also include a heat sink positioned between the first circuit board and the second circuit board and defining a speaker enclosure that includes a first portion in contact with the first circuit board, a second portion in contact with the second circuit board, and a third portion. The multimedia streaming device can additionally include a speaker installed in the third portion of the speaker enclosure.

Abstract: The disclosure relates to methods for treating cancer. More particularly, the disclosure relates to use of chimeric non-natural synthetic proteins, in combination with non-tyrosine targeting kinase inhibitors (NTKIs), in treating cancer and preventing intrinsic and/or acquired resistance to NTKIs.

Abstract: A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

Abstract: A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining Anaplastic Lymphoma Kinase Inhibitors (ALK Inhibitors) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises ALK Inhibitors administered according to a continuous regimen based on an average daily dose in the range of 10 to 250 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

Abstract: A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

Abstract: A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

Abstract: The invention includes a method and apparatus for determining the performance of a virtual concatenation group (VCG) signal transporting a client signal over a transport network. A method includes collecting a plurality of performance monitoring indicators associated with a plurality of VCG member signals of the VCG signal, synchronizing the performance monitoring indicators with respect to each other, combining the synchronized performance monitoring indicators to form VCG-level performance monitoring indicators, calculating VCG-level performance monitoring primitive measurements based on the VCG-level performance monitoring indicators, and processing the VCG-level performance monitoring primitive measurements to determine VCG performance.

Abstract: A system for transporting downstream and upstream traffic between service providers and end user terminals is provided. The system may include an apparatus having multiple egress ports configured for transmitting downstream traffic received from the service providers towards nodes adapted for replicating the traffic, at one network layer, and further transmitting the replicated traffic toward the end user terminals. The system may further include a merging unit coupled to ingress port of another apparatus receiving upstream traffic from the user end terminals, where the merging unit is adapted for merging the upstream traffic, at a different network layer, according to which service provider the upstream traffic received from the end user terminals is intended to and for transmitting the merged traffic toward the service providers.

Abstract: The invention includes an apparatus and associated method for monitoring signals. The apparatus includes a port unit including a plurality of monitoring functions associated with a respective plurality of data communication channels, and a switch unit adapted for switching signals conveyed by the data communication channels, where the switch unit includes a monitoring function controller and a plurality of monitoring function images associated with the respective monitoring functions. The monitoring function images are adapted for conveying configuration information from the monitoring function controller to the respective monitoring functions and conveying status information from the respective monitoring functions to the monitoring function controller.

Abstract: The invention comprises a method and apparatus for assigning at least one virtual concatenation group member to a virtual concatenation group at a terminating node. Specifically, the method comprises receiving originating configuration information comprising at least one assignment parameter and at least one originating capability parameter, identifying terminating configuration information associated with the terminating node where the terminating configuration information comprises at least one terminating capability parameter, comparing the at least one originating capability parameter to the at least one terminating capability parameter, and assigning the at least one virtual concatenation group member to the virtual concatenation group on the terminating node using the at least one assignment parameter in response to a determination that the at least one originating capability parameter and the at least one terminating capability parameter are compatible.

Abstract: The invention includes a method and apparatus for transporting a client signal over a transport network using enhanced virtual concatenation (VCAT) and enhanced link capacity adjustment scheme (LCAS) techniques. A method includes provisioning, for a client signal, a virtual concatenation group (VCG) signal having a VCG signal bandwidth, converting the VCG signal into a set of VCG member signals including a plurality of working VCG member signals and at least one protection VCG member signal where the set of VCG member signals has an aggregate bandwidth greater than the VCG signal bandwidth, and propagating the client signal toward the transport network using the set of VCG member signals. The client signal is initially conveyed by the working VCG member signals, and the at least one protection VCG member signal is available to protect the working VCG member signals. The client signal may be a constant bit rate (CBR) client signal.

Abstract: The invention includes a method and apparatus for determining the performance of a virtual concatenation group (VCG) signal transporting a client signal over a transport network. A method includes collecting a plurality of performance monitoring indicators associated with a plurality of VCG member signals of the VCG signal, synchronizing the performance monitoring indicators with respect to each other, combining the synchronized performance monitoring indicators to form VCG-level performance monitoring indicators, calculating VCG-level performance monitoring primitive measurements based on the VCG-level performance monitoring indicators, and processing the VCG-level performance monitoring primitive measurements to determine VCG performance.

Abstract: The invention includes an apparatus and associated method for monitoring signals. The apparatus includes a port unit including a plurality of monitoring functions associated with a respective plurality of data communication channels, and a switch unit adapted for switching signals conveyed by the data communication channels, where the switch unit includes a monitoring function controller and a plurality of monitoring function images associated with the respective monitoring functions. The monitoring function images are adapted for conveying configuration information from the monitoring function controller to the respective monitoring functions and conveying status information from the respective monitoring functions to the monitoring function controller.

Abstract: Applicant's invention is a light emitting personal lubricant whose preferred embodiment comprises a combination of personal lubricant and luminescent particles such that when said particles are activated by a light source the personal lubricant takes on “glow in the dark” characteristics, or becomes light emitting.

Abstract: The invention includes a system for transporting type one traffic downstream from a service provider router to end user terminals by replicating the type one traffic at a first network layer and transporting type two traffic upstream from the end user terminals to the service provider router by merging the type two traffic at a second network layer, where the first and second network layers are different. One apparatus according to the invention includes a plurality of unidirectional egress ports configurable for transmitting type one traffic towards a plurality of type one nodes adapted for replicating the type one configurable for receiving type two traffic, and a merging unit coupled to the plurality of unidirectional ingress ports, wherein the merging unit is adapted for merging the type two traffic at a second network layer.

Abstract: The invention comprises a method and apparatus for assigning at least one virtual concatenation group member to a virtual concatenation group at a terminating node. Specifically, the method comprises receiving originating configuration information comprising at least one assignment parameter and at least one originating capability parameter, identifying terminating configuration information associated with the terminating node where the terminating configuration information comprises at least one terminating capability parameter, comparing the at least one originating capability parameter to the at least one terminating capability parameter, and assigning the at least one virtual concatenation group member to the virtual concatenation group on the terminating node using the at least one assignment parameter in response to a determination that the at least one originating capability parameter and the at least one terminating capability parameter are compatible.

Abstract: The present invention relates to metalocarboxypeptidase inhibitors and to their natural protein variants or protein variants redesigned by engineering, as well as to peptidomimetic molecules derived from the above and used as antitumor agents.